(Q33332098)

25 July 2017

title

Docetaxel in combination with carboplatin for the treatment of advanced non-small cell lung carcinoma: a multicentre phase I study (English)

1 reference

multicenter clinical trial

25 July 2017

main subject

0 references

1 reference

1 reference

1 reference

T Giannakakis

1

1 reference

25 July 2017

N Ziras

2

1 reference

25 July 2017

S Kakolyris

3

1 reference

25 July 2017

D Mavroudis

4

1 reference

25 July 2017

N Androulakis

5

1 reference

25 July 2017

S Agelaki

6

1 reference

25 July 2017

M Parashos

7

1 reference

25 July 2017

E Sarra

8

1 reference

25 July 2017

T Dimou

9

1 reference

25 July 2017

D Hatzidaki

10

1 reference

25 July 2017

J Vlachonikolis

11

1 reference

25 July 2017

V Georgoulias

12

1 reference

25 July 2017

publication date

1 April 2000

1 reference

European Journal of Cancer

25 July 2017

published in

1 reference

25 July 2017

volume

36

1 reference

25 July 2017

issue

6

1 reference

25 July 2017

page(s)

742-747

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900005-8

25 July 2017

1 reference

7 January 2021

Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900005-8

7 January 2021

Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900005-8

7 January 2021

Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900005-8

7 January 2021

Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900005-8

7 January 2021

Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG)

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900005-8

7 January 2021

Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900005-8

7 January 2021

Docetaxel and granulocyte colony-stimulating factor in patients with advanced non-small-cell lung cancer previously treated with platinum-based chemotherapy: a multicenter phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900005-8

7 January 2021

First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: A multicenter phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900005-8

7 January 2021

Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900005-8

7 January 2021

Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900005-8

7 January 2021

Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900005-8

7 January 2021

Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900005-8

7 January 2021

Paclitaxel and carboplatin in inoperable non-small-cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900005-8

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900005-8

7 January 2021

Dose-escalation study of docetaxel in combination with mitoxantrone as first-line treatment in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900005-8

7 January 2021

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900005-8

7 January 2021

10.1016/S0959-8049(00)00005-8

Identifiers

DOI

1 reference

25 July 2017

1 reference